Can Tepezza Cause Permanent Hearing Loss? What to Know
At a Glance
Tepezza can cause hearing changes, including tinnitus, ear fullness, hearing loss, or hearing your own voice unusually loudly. Many symptoms improve after treatment, but some hearing loss may persist, so baseline audiometry and monitoring are important.
Tepezza can cause hearing changes; many improve after treatment, but some persist, and the exact chance of permanent loss is not known. Because of this risk, it is highly recommended to get a baseline hearing test before starting treatment and to monitor your hearing throughout the course of therapy [1].
Tepezza (teprotumumab) is a biologic treatment approved for thyroid eye disease [2]. While it can help manage the condition, it carries a documented risk of hearing-related adverse effects (sometimes referred to as ototoxicity). Clinical trials and real-world studies show that a portion of people receiving the drug experience new ear or hearing-related symptoms [3]. These symptoms often emerge around the third to sixth infusion, though they can occur earlier, later, or even after the treatment course is finished [4][5].
Common Hearing Symptoms
If you are taking Tepezza, it is important to be aware of the specific auditory symptoms that can occur. These include:
- Subjective hearing loss: A gradual decrease in your ability to hear or comprehend words, often in both ears [6][4].
- Tinnitus: A ringing, buzzing, or roaring sound in the ears [6][7].
- Autophony: Hearing your own voice, breathing, or bodily sounds unusually loudly [4][8].
- Aural fullness: A feeling that your ears are plugged or under pressure [9][4].
Are the Hearing Changes Permanent?
The reversibility of these side effects often depends on the specific symptom. Transient symptoms like tinnitus, ear fullness, and autophony frequently resolve entirely or significantly improve within weeks or months after the final infusion [4].
However, subjective and measured hearing loss is less consistently reversible [4][6]. In a 2026 meta-analysis combining multiple studies, researchers estimated that among patients who already developed hearing symptoms, roughly 39% had persistent hearing impairment at their last medical follow-up [10]. It is important to note that “persistent at the last follow-up” is not necessarily the same as permanent, and follow-up times varied across the studies.
Still, several case reports have documented persistent, potentially irreversible sensorineural hearing loss (nerve-related hearing damage) that did not improve even after the medication was stopped [11][12][13]. Some studies also show that patients’ hearing thresholds may partially recover after treatment but may not return completely to their pre-treatment baseline [14][6]. While case reports occasionally describe patients receiving steroids for this hearing loss, there is no proven, guaranteed medical treatment to reverse it [15].
The Importance of a Baseline Audiogram and Monitoring
Because of the risk of persistent changes, clinical experts strongly recommend undergoing a comprehensive baseline hearing assessment before starting Tepezza [1][4]. A baseline evaluation should ideally include:
- Audiometry (Audiogram): A formal hearing test to measure your ability to hear different sound frequencies.
- Word-recognition testing: To evaluate how well you understand spoken words.
- Tympanometry: To measure how well your eardrum moves and check for eustachian tube dysfunction (problems with the tube connecting your middle ear to the back of your throat) [1].
This baseline testing is critical because subjective symptoms do not always accurately reflect the physical changes happening in the ear; some patients show measurable high-frequency hearing loss on tests before they even notice a change in their hearing [16][17]. Having a baseline allows your medical team (which should ideally include your prescribing doctor and an audiologist or Ear, Nose, and Throat specialist) to compare your hearing during and after treatment.
Some studies suggest that older adults and patients who have a prior history of hearing loss may be at a higher risk of developing hearing complications from Tepezza [4][5].
What to Do If Symptoms Occur
- Report gradual changes promptly: If you develop new tinnitus, ear fullness, or gradual hearing changes, notify your prescribing doctor so they can arrange for repeat audiometry.
- Do not stop treatment independently: Do not skip or stop an infusion on your own. Discuss pausing or adjusting treatment with your medical team, as this is a shared, individualized decision based on the severity of your eye disease versus the risk to your hearing.
- Seek urgent care for sudden changes: If you experience sudden hearing loss (especially in just one ear) or sudden severe dizziness/vertigo, this is a medical emergency. Seek same-day urgent care or an emergency Ear, Nose, and Throat (ENT) evaluation. Do not wait for your next routine infusion appointment [12].
Common questions in this guide
Can hearing loss from Tepezza be permanent?
When do Tepezza-related hearing problems usually start?
What hearing tests should I have before starting Tepezza?
What should I do if my hearing changes while I am receiving Tepezza?
Is sudden hearing loss during Tepezza an emergency?
Do age or previous hearing problems affect the risk from Tepezza?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Related questions
Show more
Get notified when new evidence is published on thyrotoxic exophthalmos.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is your recommended schedule for audiograms before, during, and after my Tepezza treatment?
- 2.If I develop new hearing symptoms, at what point would we consider pausing or stopping the infusions?
- 3.Who should I contact after-hours if I experience sudden hearing loss or severe vertigo?
- 4.Given my age and personal history of hearing or ear issues, am I at a higher risk for these side effects?
- 5.How will we balance the potential risks to my hearing with the benefits of treating my Thyroid Eye Disease, and what are my alternatives?
References
References (17)
- 1
Teprotumumab and Hearing Loss: Case Series and Proposal for Audiologic Monitoring.
Belinsky I, Creighton FX, Mahoney N, et al.
Ophthalmic plastic and reconstructive surgery 2022; (38(1)):73-78 doi:10.1097/IOP.0000000000001995.
PMID: 34085994 - 2
Association Between Teprotumumab and Hearing Impairment: A Meta-Analysis.
Barnett MJ, deMelo M, Rego M, Casipit C
Cureus 2026; (18(2)):e102775 doi:10.7759/cureus.102775.
PMID: 41630971 - 3
Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
Winn BJ, Kersten RC
Ophthalmology 2021; (128(11)):1627-1651 doi:10.1016/j.ophtha.2021.04.024.
PMID: 33930408 - 4
Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease.
Sears CM, Azad AD, Amarikwa L, et al.
American journal of ophthalmology 2022; (240()):1-13 doi:10.1016/j.ajo.2022.02.015.
PMID: 35227694 - 5
Frequency and Patterns of Hearing Dysfunction in Patients Treated with Teprotumumab.
Keen JA, Correa T, Pham C, et al.
Ophthalmology 2024; (131(1)):30-36 doi:10.1016/j.ophtha.2023.08.001.
PMID: 37567417 - 6
Otologic Symptoms Following Teprotumumab Administration in Patients with Thyroid Eye Disease.
Epperson MV, Hughes S, Valenzuela CV, Stucken EZ
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2025; (46(3)):330-335 doi:10.1097/MAO.0000000000004418.
PMID: 39951668 - 7
A Biologic With Otologic Consequences: Analysis of Hearing Loss and Teprotumumab Using the FDA Adverse Event Reporting System.
Huynh PP, Saba E, Rivero A, et al.
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2024; (45(8)):e566-e569 doi:10.1097/MAO.0000000000004260.
PMID: 39142306 - 8
Postmarketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment.
Huang J, Su A, Yang J, et al.
The Journal of clinical endocrinology and metabolism 2024; (110(1)):159-165 doi:10.1210/clinem/dgae417.
PMID: 38878281 - 9
Patterns of Teprotumumab-Induced Hearing Dysfunction: A Systematic Review.
Wong K, Arya P, Salmeron Y, et al.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2025; (173(3)):539-545 doi:10.1002/ohn.955.
PMID: 39194388 - 10
Incidence and characteristics of teprotumumab-associated ototoxicity in thyroid eye disease: A systematic review and meta-analysis.
Lee SH, Kuo LY, Tsai TH
Survey of ophthalmology 2026; doi:10.1016/j.survophthal.2026.09.005.
PMID: 42778038 - 11
Ototoxicity and Teprotumumab.
Highland J, Gordon S, Reddy D, Patel N
The Annals of otology, rhinology, and laryngology 2022; (131(8)):910-913 doi:10.1177/00034894211042740.
PMID: 34448414 - 12
Teprotumumab-associated chronic hearing loss screening and proposed treatments.
Chow A, Silkiss RZ
BMJ case reports 2022; (15(4)) doi:10.1136/bcr-2021-248335.
PMID: 35418378 - 13
Teprotumumab-associated persistent unilateral hearing loss in dysthyroid optic neuropathy: a case report with review of the literature.
Hiromatsu Y, Suzuki K, Watanabe S, et al.
Endocrine journal 2026; doi:10.1507/endocrj.EJ26-0064.
PMID: 42386595 - 14
Audiometric changes during teprotumumab therapy for thyroid eye disease: a prospective pilot study.
Van Swol J, Spinello J, Bimali M, et al.
Endocrine 2026; (91(1)).
PMID: 42455407 - 15
Oral Corticosteroids for Teprotumumab-Related Hearing Loss: A Case Report.
Lu TJ, Amarikwa L, Winn BJ, et al.
Case reports in ophthalmology 2023; (14(1)):134-139 doi:10.1159/000529422.
PMID: 37034380 - 16
Prospective Assessment of Otologic Adverse Events due to Teprotumumab: Preliminary Results.
Kay-Rivest E, Belinsky I, Kozlova A, et al.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2023; (168(5)):1164-1169 doi:10.1002/ohn.174.
PMID: 36939482 - 17
Audiology findings in patients with teprotumumab associated otologic symptoms.
Yu CY, Correa T, Simmons BA, et al.
American journal of ophthalmology case reports 2021; (24()):101202 doi:10.1016/j.ajoc.2021.101202.
PMID: 34585021
This page is for informational purposes only and does not constitute medical advice. Your prescribing clinician, audiologist, or ENT should interpret your hearing tests and guide decisions about Tepezza treatment.